Company news
Cambium Bio Ltd news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Regeneus Market Update
December 21, 2021
Regeneus Announces Institutional Placement
May 6, 2021
Appendix 4C - Quarterly
April 30, 2021
Regeneus partners with Defence to treat combat casualties
April 29, 2021
Regeneus to be granted key Progenza patent in Europe
March 15, 2021
Regeneus Company Update Investor Webcast Presentation
March 2, 2021
Half-Year Results and Business Update
February 26, 2021
Appendix 4D and Half-Year Report
February 26, 2021
Regeneus to be granted new patent to target pain in Japan
February 8, 2021
Response to ASX Appendix 4C Query
February 4, 2021
Appendix 4C - Quarterly Report
January 28, 2021
Clarification on Quarterly Activity Report and Appendix 4C
November 10, 2020
CEO Appointment and Resignation
November 1, 2020
Regeneus receives $5.6M milestone payment from Kyocera
October 29, 2020
Regeneus to be granted new Sygenus patent in Canada
October 6, 2020
Regeneus receives milestone payment from Kyocera
August 28, 2020
Appendix 4E and Annual Report
August 28, 2020
Regeneus to present at FNN Virtual Investor Event
August 25, 2020
US Patent for Sygenus
August 18, 2020
Regeneus and Kyocera sign Progenza OA deal
August 11, 2020
Progenza OA Kyocera negotiations update
July 27, 2020
Kyocera completes Progenza Due Diligence
May 17, 2020
Appendix 4C Updated
May 5, 2020
Regeneus to be granted new key Progenza patent in U.S.
March 22, 2020
Regeneus receives A$1.6M milestone payment from Kyocera
March 19, 2020
Regeneus signs MOU with Kyocera Corporation
March 1, 2020
Half-Year Results & Business Update
February 28, 2020
Directors provide $4m loan facility
February 28, 2020
AGC Agreement termination paves way for commercial partner
December 19, 2019
CEO Presentation to 2019 Annual General Meeting
November 21, 2019
Chairmans Address to Shareholders
November 21, 2019
Japanese Biotech Fund takes up all Rights Issue Shortfall
November 19, 2019
Regeneus receives A$1.5 million in R&D Tax Incentives
October 15, 2019
Appendix 4E
August 29, 2019
Restructuring results in 50% reduction in operating costs
August 13, 2019
Updated Investor Presentation
August 7, 2019
Offer Booklet
August 1, 2019
Investor Presentation
August 1, 2019
Successful Private Placement
August 1, 2019
Positive results for Progenza in treating neuropathic pain
July 23, 2019
Directors Provide $2.5M Loan to Extend Funding Runway
February 28, 2019
Response to ASX Appendix 4C Query Letter
February 21, 2019
New CEO Appointed to Accelerate Global Growth
January 22, 2019
Chinese patent granted for biomarkers for stem cell therapy
December 2, 2018
Re-Released - Appendix 4C - Quarterly
October 23, 2018
Progenza patent to grant in Europe
October 17, 2018
Regeneus receives R&D tax incentive refund of $2.4m
September 5, 2018
Positive clinical trial results for cancer vaccine
July 30, 2018
US Patent Office to allow key patent for Progenza
July 9, 2018
Update on licensing Progenza in Japan
July 3, 2018
Decks
The 5 newest of 7 decks. Every deck is listed under its year.
- Investor Presentation (September 2026)
Investor deck · 29 slides · Sep 30, 2026
- Corporate Update (September 2023)
Corporate update · 16 slides · Sep 28, 2023
- Corporate Update (March 2021)
Corporate update · 26 slides · Mar 3, 2021
- Shareholder Meeting (November 2019)
Shareholder meeting · 16 slides · Nov 21, 2019
- Investor Presentation (August 2019)
Investor deck · 13 slides · Aug 7, 2019